{
  "_metadata": {
    "version": "2.0",
    "extracted_from": "Kymera Therapeutics Corporate Presentation January 2026",
    "extraction_date": "2026-02-04",
    "analyst_reviewed": true
  },
  "asset": {
    "name": "KT-621",
    "company": "Kymera Therapeutics",
    "ticker": "KYMR",
    "stage": "Phase 2b",
    "modality": "Heterobifunctional degrader",
    "ownership": "Wholly-owned",
    "one_liner": "Dupilumab-like activity in a pill - first oral STAT6 degrader"
  },
  "target": {
    "name": "STAT6",
    "full_name": "Signal Transducer and Activator of Transcription 6",
    "class": "Transcription Factor",
    "pathway": "IL-4/IL-13 \u2192 Type 2 inflammation",
    "biology": {
      "simple_explanation": "STAT6 is THE transcription factor for IL-4/IL-13 signaling. When IL-4 or IL-13 binds to receptors on cells, STAT6 gets activated, moves to the nucleus, and turns on all the genes that cause allergic inflammation.",
      "pathway_detail": "IL-4 binds IL-4R\u03b1 + \u03b3C receptor complex. IL-13 binds IL-4R\u03b1 + IL-13R\u03b11 complex. Both activate JAK1/JAK3, which phosphorylate STAT6. Phospho-STAT6 dimerizes, translocates to nucleus, and drives transcription of Type 2 inflammation genes.",
      "downstream_effects": [
        "IgE class switching in B cells",
        "Th2 differentiation",
        "Mucus production",
        "Eosinophil recruitment",
        "Skin barrier dysfunction"
      ]
    },
    "why_good_target": {
      "clinical_validation": "Dupilumab (anti-IL-4R\u03b1) validates this pathway with $13B+ in sales. Approved in AD, asthma, COPD, EoE, CRSwNP, CSU, PN, BP.",
      "genetic_validation": {
        "gain_of_function": "STAT6 GoF mutations cause hyper-IgE syndrome and severe allergic disease",
        "loss_of_function": "STAT6 heterozygous LoF alleles protect against allergic disease"
      },
      "source": {
        "id": "kymr_corporate_2026",
        "slide": 14,
        "verified": false
      }
    },
    "why_undruggable_before": {
      "challenge": "Transcription factors lack enzymatic pockets for traditional small molecule inhibitors to bind",
      "previous_attempts": "No known drugs selectively target this pathway with oral delivery potential",
      "degrader_solution": "TPD allows elimination of entire protein, achieving complete pathway blockade equivalent to biologics"
    },
    "dupilumab_comparison": {
      "dupilumab_mechanism": "Blocks IL-4R\u03b1 receptor upstream",
      "kt621_mechanism": "Destroys STAT6 transcription factor downstream",
      "expected_result": "Both should achieve same pathway blockade, but KT-621 is oral"
    }
  },
  "mechanism": {
    "type": "Heterobifunctional degrader (PROTAC)",
    "e3_ligase": "Cereblon (CRBN)",
    "how_it_works": "KT-621 is a bifunctional molecule with one end that binds STAT6 and another end that recruits the Cereblon E3 ligase. This brings STAT6 to the cell's protein disposal system (proteasome), which destroys it. One KT-621 molecule can catalytically destroy many STAT6 proteins.",
    "catalytic_advantage": "Unlike traditional inhibitors (stoichiometric, need continuous high exposure), degraders work catalytically - low/short drug exposures achieve sustained target elimination",
    "potency": {
      "dc90": "<100 pM in all relevant human cell types",
      "interpretation": "Sub-nanomolar potency means very low doses needed"
    },
    "selectivity": "Highly selective for STAT6 - proteomics shows STAT6 is ONLY protein significantly degraded",
    "tissue_distribution": {
      "blood": "Confirmed deep degradation",
      "skin": "Confirmed penetration via punch biopsies - critical for dermatology"
    },
    "source": {
      "id": "kymr_corporate_2026",
      "slide": 56,
      "verified": false
    }
  },
  "indications": {
    "lead": {
      "name": "Atopic Dermatitis",
      "patient_population": "43M adults in US/EU5/JP",
      "current_penetration": "<1% on advanced systemic therapy",
      "rationale": "Largest Type 2 market, Dupixent validated, high unmet need"
    },
    "expansion": [
      {
        "name": "Asthma",
        "patient_population": "55M",
        "status": "Phase 2b initiated",
        "rationale": "Second largest market, Dupixent approved"
      },
      {
        "name": "COPD",
        "patient_population": "34M",
        "rationale": "Dupixent recently approved"
      },
      {
        "name": "Eosinophilic Esophagitis (EoE)",
        "patient_population": "1.6M",
        "rationale": "Dupixent approved"
      },
      {
        "name": "Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)",
        "patient_population": "2.8M",
        "rationale": "Dupixent approved"
      },
      {
        "name": "Chronic Spontaneous Urticaria (CSU)",
        "patient_population": "4.4M",
        "rationale": "Dupixent approved"
      },
      {
        "name": "Prurigo Nodularis (PN)",
        "patient_population": "305K",
        "rationale": "Dupixent approved"
      },
      {
        "name": "Bullous Pemphigoid (BP)",
        "patient_population": "166K",
        "rationale": "Dupixent approved"
      }
    ],
    "total_addressable_patients": ">140M",
    "development_strategy": "Parallel Phase 2b in AD + Asthma enables Phase 3 across multiple dermatology, GI, and respiratory indications with same dose",
    "source": {
      "id": "kymr_corporate_2026",
      "slide": 15,
      "verified": false
    }
  },
  "market_opportunity": {
    "total_addressable_market": ">$27B by 2030",
    "current_penetration": "Only ~1% of patients on advanced systemic therapy",
    "oral_preference": ">90% of biologic patients would switch to oral option",
    "peak_sales_estimate": {
      "bull_case": "$5B+",
      "base_case": "$3B",
      "bear_case": "$1B"
    },
    "competitive_advantage": "Oral convenience could expand market penetration from 1% to 10%+",
    "source": {
      "id": "kymr_corporate_2026",
      "slide": 13,
      "verified": false
    }
  },
  "clinical_data": {
    "phase1_healthy_volunteer": {
      "trial_name": "Phase 1 SAD/MAD",
      "design": {
        "type": "Randomized, placebo-controlled, dose-escalation",
        "population": "Healthy volunteers",
        "sad_n": 48,
        "mad_n": 70,
        "dosing": "Single ascending dose and multiple ascending dose (14 days)"
      },
      "stat6_degradation": {
        "description": "Primary PD endpoint measuring target engagement",
        "methods": {
          "blood": "Flow cytometry",
          "skin": "Targeted mass spectrometry on punch biopsies"
        },
        "results_by_dose": [
          {
            "dose": "Placebo",
            "blood_change": "~0%",
            "skin_change": "~0%",
            "n_blood": 18,
            "n_skin": 17
          },
          {
            "dose": "1.5mg QD",
            "blood_change": "~-20%",
            "skin_change": "~-10%",
            "n_blood": 9,
            "n_skin": 7
          },
          {
            "dose": "12.5mg QD",
            "blood_change": "~-70%",
            "skin_change": "~-60%",
            "n_blood": 7,
            "n_skin": 7
          },
          {
            "dose": "25mg QD",
            "blood_change": ">-90%",
            "skin_change": ">-90%",
            "n_blood": 9,
            "n_skin": 8
          },
          {
            "dose": "50mg QD",
            "blood_change": ">-90%",
            "skin_change": ">-90%",
            "n_blood": 9,
            "n_skin": 9
          },
          {
            "dose": "100mg QD",
            "blood_change": ">-90%",
            "skin_change": ">-90%",
            "n_blood": 9,
            "n_skin": 9
          },
          {
            "dose": "200mg QD",
            "blood_change": ">-90%",
            "skin_change": ">-90%",
            "n_blood": 9,
            "n_skin": 9
          }
        ],
        "key_findings": [
          "Clear dose-response from 1.5mg to 25mg",
          "Plateau at \u226525mg - maximal degradation achieved",
          "Skin penetration confirmed - critical for dermatology indication",
          "100mg vs 200mg equivalent - suggests 100mg sufficient"
        ],
        "source": {
          "id": "kymr_corporate_2026",
          "slide": 22,
          "verified": false
        }
      },
      "biomarker_results": {
        "tarc": {
          "full_name": "Thymus and Activation-Regulated Chemokine (CCL17)",
          "what_it_measures": "Validated biomarker of Type 2 inflammation; recruits inflammatory T cells",
          "method": "Serum ELISA",
          "result_at_200mg_day14": "-40%",
          "vs_dupilumab": "Dupilumab achieves -70% at Week 4 in patients (these are healthy volunteers)",
          "interpretation": "Dose-dependent reduction; progressive improvement over 14 days without plateau"
        },
        "eotaxin3": {
          "full_name": "Eotaxin-3 (CCL26)",
          "what_it_measures": "Highly specific IL-4/IL-13 downstream marker; recruits eosinophils",
          "method": "Serum ELISA",
          "result_at_200mg_day14": "-70%",
          "interpretation": "Stronger response than TARC; predicts efficacy in EoE and asthma"
        }
      },
      "safety": {
        "summary": "Well-tolerated across all doses; safety profile undifferentiated from placebo",
        "sad_aes": {
          "placebo_headache": "1/12 (8.3%)",
          "kt621_headache": "0/36"
        },
        "mad_aes": {
          "placebo_nausea": "1/18 (5.6%)",
          "kt621_nausea": "0/52",
          "kt621_asthenia": "1/52 (1.9%)"
        },
        "key_findings": [
          "No SAEs",
          "No Severe AEs",
          "No dose-dependent pattern in TEAEs",
          "No TRAE reported in >1 participant",
          "No discontinuations due to AEs",
          "No clinically relevant changes in vitals, labs, ECGs"
        ],
        "source": {
          "id": "kymr_corporate_2026",
          "slide": 57,
          "verified": false
        }
      }
    },
    "phase1b_ad": {
      "trial_name": "BroADen Phase 1b",
      "design": {
        "type": "Single arm, open label",
        "population": "Adult moderate-to-severe AD patients",
        "n_enrolled": 22,
        "dosing": "Oral, once daily for 28 days",
        "follow_up": "14 days after dosing completed",
        "cohorts": [
          {
            "dose": "100mg QD",
            "n": 10
          },
          {
            "dose": "200mg QD",
            "n": 12
          }
        ]
      },
      "design_limitations": [
        "Open-label - no placebo arm",
        "AD has 25-35% placebo response rate",
        "Small sample size (n=22)",
        "Short duration (29 days vs 16 weeks for registration)",
        "Cross-trial comparison to Dupixent has caveats"
      ],
      "inclusion_criteria": [
        "EASI \u226516",
        "vIGA-AD \u22653",
        "Peak Pruritus NRS \u22654",
        "BSA \u226510%",
        "Documented TCS failure",
        "Prior biologics allowed after washout if patient responded"
      ],
      "baseline_characteristics": {
        "age_mean": 31.7,
        "female_pct": 59.1,
        "bmi_mean": 31.7,
        "race_white_pct": 31.8,
        "race_black_pct": 54.5,
        "viga_moderate_pct": 54.5,
        "viga_severe_pct": 45.5,
        "easi_mean": 24.9,
        "ppnrs_mean": 7.5,
        "scorad_mean": 60.1,
        "bsa_mean_pct": 29.6,
        "comorbid_asthma_pct": 18.2,
        "comorbid_allergic_rhinitis_pct": 40.9,
        "prior_systemic_therapy_pct": 22.7,
        "analyst_note": "45.5% severe patients and prior biologic use shows this is a sick, treatment-experienced population",
        "source": {
          "id": "kymr_corporate_2026",
          "slide": "58-59",
          "verified": false
        }
      },
      "efficacy_endpoints": {
        "stat6_degradation": {
          "blood": {
            "method": "Flow cytometry",
            "result_100mg_day29": "-98%",
            "result_200mg_day29": "-98%",
            "time_course": "Deep degradation by Day 8, maintained through Day 29",
            "interpretation": "Near-complete target elimination in both dose groups"
          },
          "skin": {
            "method": "Targeted mass spectrometry",
            "result_100mg_day29": "-94%",
            "result_200mg_day29": "-94%",
            "note": "Multiple patients below LLOQ (lower limit of quantification)",
            "interpretation": "Confirms drug penetrates target tissue"
          },
          "source": {
            "id": "kymr_corporate_2026",
            "slide": 25,
            "verified": false
          }
        },
        "easi": {
          "full_name": "Eczema Area and Severity Index",
          "what_it_measures": "Composite of affected BSA \u00d7 severity (erythema, induration, excoriation, lichenification) across 4 body regions",
          "scoring": "0-72 scale; higher = worse",
          "regulatory_status": "FDA-accepted primary endpoint for AD trials",
          "results": {
            "mean_change_100mg_day29": "-62%",
            "mean_change_200mg_day29": "-63%",
            "mean_change_overall_day29": "-63%",
            "vs_dupilumab_day28_ph3": "-52%",
            "easi50_overall": "76%",
            "easi50_vs_dupilumab": "57%",
            "easi75_overall": "29%",
            "easi75_vs_dupilumab": "28%"
          },
          "time_course": [
            {
              "day": 1,
              "change": "0%"
            },
            {
              "day": 8,
              "change": "~-27%"
            },
            {
              "day": 15,
              "change": "~-45%"
            },
            {
              "day": 22,
              "change": "~-55%"
            },
            {
              "day": 29,
              "change": "-63%"
            },
            {
              "day": 43,
              "change": "~-55%",
              "note": "14 days off treatment"
            }
          ],
          "key_observations": [
            "Rapid onset - ~30% improvement by Day 8",
            "No plateau at Day 29 - curve still improving",
            "100mg = 200mg - no dose-response at these levels",
            "Some durability - still -55% at Day 43 (off treatment)"
          ],
          "source": {
            "id": "kymr_corporate_2026",
            "slide": 28,
            "verified": false
          }
        },
        "viga_ad": {
          "full_name": "Validated Investigator Global Assessment for AD",
          "what_it_measures": "Physician assessment of overall disease severity",
          "scoring": "0 (clear) to 4 (severe)",
          "target": "0 or 1 (clear or almost clear)",
          "results": {
            "responders_100mg": "22%",
            "responders_200mg": "17%",
            "responders_overall": "19%",
            "vs_dupilumab": "12%"
          },
          "source": {
            "id": "kymr_corporate_2026",
            "slide": 33,
            "verified": false
          }
        },
        "ppnrs": {
          "full_name": "Peak Pruritus Numerical Rating Scale",
          "what_it_measures": "Patient-reported worst itch in past 24 hours",
          "scoring": "0-10 scale; higher = worse",
          "clinical_importance": "Itch is most bothersome symptom for patients",
          "results": {
            "mean_change_100mg": "-47%",
            "mean_change_200mg": "-35%",
            "mean_change_overall": "-40%",
            "vs_dupilumab": "-33%"
          },
          "source": {
            "id": "kymr_corporate_2026",
            "slide": 29,
            "verified": false
          }
        },
        "scorad": {
          "full_name": "SCORing Atopic Dermatitis",
          "results": {
            "total_change_overall": "-48%",
            "vs_dupilumab": "-41%",
            "itch_change_overall": "-44%",
            "sleeplessness_change_overall": "-76%"
          },
          "source": {
            "id": "kymr_corporate_2026",
            "slide": "28-30",
            "verified": false
          }
        },
        "bsa": {
          "full_name": "Body Surface Area affected",
          "results": {
            "mean_change_overall": "-49%",
            "vs_dupilumab": "-36%"
          },
          "source": {
            "id": "kymr_corporate_2026",
            "slide": 33,
            "verified": false
          }
        },
        "poem": {
          "full_name": "Patient-Oriented Eczema Measure",
          "what_it_measures": "Patient-reported disease severity and experience",
          "mcid": "4 points improvement",
          "results": {
            "responders_100mg": "70%",
            "responders_200mg": "75%",
            "responders_overall": "73%",
            "vs_dupilumab_week16": "69%"
          },
          "source": {
            "id": "kymr_corporate_2026",
            "slide": 30,
            "verified": false
          }
        },
        "dlqi": {
          "full_name": "Dermatology Life Quality Index",
          "what_it_measures": "Quality of life impact",
          "mcid": "4 points improvement",
          "results": {
            "responders_100mg": "57%",
            "responders_200mg": "64%",
            "responders_overall": "61%",
            "vs_dupilumab_week16": "69%"
          },
          "source": {
            "id": "kymr_corporate_2026",
            "slide": 30,
            "verified": false
          }
        }
      },
      "biomarker_results": {
        "summary_table": {
          "source": {
            "id": "kymr_corporate_2026",
            "slide": 26,
            "verified": false
          },
          "data": [
            {
              "biomarker": "TARC (CCL17)",
              "what_it_measures": "Validated Type 2 marker; T cell chemotaxis",
              "kt621_result": "-74%",
              "dupilumab_result": "-74%",
              "interpretation": "Matches Dupilumab exactly - key validation"
            },
            {
              "biomarker": "Eotaxin-3 (CCL26)",
              "what_it_measures": "Eosinophil chemotaxis; highly specific to IL-4/13",
              "kt621_result": "-73%",
              "dupilumab_result": "-51% (in asthma)",
              "interpretation": "BEATS Dupilumab (though different populations)"
            },
            {
              "biomarker": "IgE",
              "what_it_measures": "Allergic antibody; B cell class switching",
              "kt621_result": "-14%",
              "dupilumab_result": "~15%",
              "interpretation": "Similar to Dupilumab"
            },
            {
              "biomarker": "IL-31",
              "what_it_measures": "Pruritogenic (itch) cytokine",
              "kt621_result": "-54%",
              "dupilumab_result": "Not measured",
              "interpretation": "Explains itch improvement - IL-31 is the 'itch cytokine'"
            },
            {
              "biomarker": "FeNO",
              "what_it_measures": "Fractional exhaled NO; airway Type 2 inflammation",
              "kt621_result": "-33%",
              "dupilumab_result": "Not measured in AD",
              "interpretation": "Suggests potential asthma efficacy"
            }
          ]
        },
        "skin_transcriptomics": {
          "description": "Core Type 2 inflammation gene signature in skin lesions",
          "genes_measured": [
            "CCL26/Eotaxin-3",
            "CCL17/TARC",
            "CCL18/PARC",
            "CCL13/MCP-4"
          ],
          "result": "Significant downregulation from Day 1 to Day 29",
          "p_value": "<0.01",
          "vs_dupilumab": "Changes comparable to published Dupilumab data at Week 4",
          "interpretation": "Objective molecular evidence of disease modification at tissue level",
          "source": {
            "id": "kymr_corporate_2026",
            "slide": 27,
            "verified": false
          }
        }
      },
      "comorbid_asthma_data": {
        "n": 4,
        "feno": {
          "full_name": "Fractional Exhaled Nitric Oxide",
          "what_it_measures": "Airway Type 2 inflammation marker",
          "result": "-56% median at Day 29",
          "vs_dupilumab_asthma": "-31% at Week 4",
          "interpretation": "KT-621 BEATS Dupilumab on this biomarker"
        },
        "acq5": {
          "full_name": "Asthma Control Questionnaire",
          "mcid": "0.5 points",
          "mean_change": "-1.2 points",
          "responder_rate": "100% (4/4)",
          "interpretation": "All patients had clinically meaningful improvement"
        },
        "caveat": "Only 4 patients - directionally positive but small n",
        "source": {
          "id": "kymr_corporate_2026",
          "slide": 31,
          "verified": false
        }
      },
      "comorbid_allergic_rhinitis_data": {
        "tnss": {
          "full_name": "Total Nasal Symptom Score",
          "n": 7,
          "mean_change": "-0.9 points",
          "responders": "57%",
          "mcid": "0.55 points"
        },
        "rqlq": {
          "full_name": "Rhinoconjunctivitis Quality of Life Questionnaire",
          "n": 6,
          "mean_change": "-0.8 points",
          "responders": "33%",
          "mcid": "0.5 points"
        },
        "source": {
          "id": "kymr_corporate_2026",
          "slide": 32,
          "verified": false
        }
      },
      "safety": {
        "summary": "Well-tolerated with favorable safety at both doses; profile similar to Phase 1 HV",
        "key_findings": [
          "No SAEs",
          "No Severe AEs",
          "No dose-dependent pattern in TEAEs",
          "No related TEAEs leading to discontinuation",
          "No conjunctivitis (or any ocular disorder) - KEY vs Dupixent",
          "No herpes infections",
          "No arthralgias",
          "No clinically relevant changes in vitals, labs, ECGs"
        ],
        "conjunctivitis_comparison": {
          "kt621": "0%",
          "dupilumab": "10-25%",
          "interpretation": "Potential safety differentiation - conjunctivitis limits Dupixent use in some patients"
        },
        "source": {
          "id": "kymr_corporate_2026",
          "slide": 34,
          "verified": false
        }
      },
      "head_to_head_comparison_table": {
        "description": "KT-621 vs Dupilumab at similar timepoints",
        "caveat": "Cross-trial comparison - no head-to-head conducted",
        "source": {
          "id": "kymr_corporate_2026",
          "slide": 33,
          "verified": false
        },
        "data": [
          {
            "endpoint": "Mean % Change EASI",
            "kt621_day29": "-63%",
            "dupilumab_day28": "-52%",
            "winner": "KT-621"
          },
          {
            "endpoint": "EASI-50",
            "kt621_day29": "76%",
            "dupilumab_day28": "57%",
            "winner": "KT-621"
          },
          {
            "endpoint": "EASI-75",
            "kt621_day29": "29%",
            "dupilumab_day28": "28%",
            "winner": "Tie"
          },
          {
            "endpoint": "Mean % Change PP-NRS",
            "kt621_day29": "-40%",
            "dupilumab_day28": "-33%",
            "winner": "KT-621"
          },
          {
            "endpoint": "Mean % Change SCORAD",
            "kt621_day29": "-48%",
            "dupilumab_day28": "-41%",
            "winner": "KT-621"
          },
          {
            "endpoint": "vIGA-AD 0/1",
            "kt621_day29": "19%",
            "dupilumab_day28": "12%",
            "winner": "KT-621"
          },
          {
            "endpoint": "Mean % Change BSA",
            "kt621_day29": "-49%",
            "dupilumab_day28": "-36%",
            "winner": "KT-621"
          }
        ]
      }
    },
    "ongoing_trials": [
      {
        "trial_name": "BROADEN2",
        "phase": "Phase 2b",
        "indication": "Moderate-to-severe Atopic Dermatitis",
        "design": {
          "type": "Randomized, double-blind, placebo-controlled, dose-ranging",
          "n_target": "~200 patients",
          "population": "Adults and adolescents ages 12-75",
          "dosing": "Daily dose for 16 weeks + 52-week open label extension",
          "arms": "Three KT-621 doses + placebo (1:1:1:1)"
        },
        "inclusion_criteria": [
          "EASI \u226516",
          "vIGA-AD \u22653",
          "Peak Pruritus NRS \u22654",
          "BSA \u226510%",
          "Documented TCS failure"
        ],
        "endpoints": {
          "primary": "Percent change from baseline in EASI score at Week 16",
          "secondary": [
            "EASI-50",
            "EASI-75",
            "vIGA-AD 0/1",
            "\u22654-point improvement in Peak Pruritus NRS"
          ]
        },
        "status": "Ongoing, also including adolescents",
        "data_expected": "Mid-2027",
        "key_trial_aim": "Establish clinical activity and safety to select Phase 3 dose for registrational studies in multiple dermatological and GI indications",
        "what_success_looks_like": {
          "easi75_target": "\u226540%",
          "placebo_delta_target": "\u226515%",
          "safety": "Maintain clean profile"
        },
        "what_failure_looks_like": {
          "easi75_below": "<30%",
          "small_placebo_delta": "<10%",
          "safety_signal": "Emergence of conjunctivitis or other concerning AEs"
        },
        "source": {
          "id": "kymr_corporate_2026",
          "slide": 19,
          "verified": false
        }
      },
      {
        "trial_name": "BREADTH",
        "phase": "Phase 2b",
        "indication": "Moderate-to-severe Eosinophilic Asthma",
        "design": {
          "type": "Randomized, double-blind, placebo-controlled, dose-ranging",
          "n_target": "~264 patients",
          "population": "Adults",
          "dosing": "Daily dose for 12 weeks",
          "arms": "Three KT-621 doses + placebo (1:1:1:1)"
        },
        "inclusion_criteria": [
          "Blood eosinophils \u2265300 cells/\u00b5L",
          "FeNO \u226525 ppb",
          "Pre-bronchodilator FEV1 40-80% of predicted"
        ],
        "endpoints": {
          "primary": "Percent change from baseline in pre-bronchodilator FEV1 at Week 12",
          "secondary": [
            "Change from baseline in ACQ-5",
            "Change from baseline in AQLQ"
          ]
        },
        "status": "Initiated January 2026",
        "data_expected": "Late 2027",
        "key_trial_aim": "Establish clinical activity and safety to select Phase 3 dose for respiratory indications",
        "why_it_matters": "Proves platform works beyond skin; validates respiratory opportunity",
        "source": {
          "id": "kymr_corporate_2026",
          "slide": 20,
          "verified": false
        }
      }
    ]
  },
  "preclinical_data": {
    "potency": {
      "dc90": "<100 pM in all relevant human cell types",
      "interpretation": "Exceptional potency - very low doses needed"
    },
    "selectivity": {
      "description": "Proteomics volcano plot shows STAT6 is ONLY protein significantly degraded",
      "off_targets": "None identified"
    },
    "comparison_to_dupilumab": {
      "il4_signaling": "Blocked equally or more potently than Dupilumab",
      "il13_signaling": "Blocked equally or more potently than Dupilumab",
      "in_vivo_efficacy": "Comparable or superior to Dupilumab in HDM asthma model"
    },
    "safety_pharmacology": {
      "rat_4week": "No AEs at any dose",
      "nhp_4week": "No AEs at any dose",
      "rat_4month": "No AEs at any dose",
      "nhp_4month": "No AEs at any dose",
      "embryofetal_rat": "No toxicity",
      "embryofetal_rabbit": "No toxicity",
      "embryofetal_nhp": "No toxicity",
      "safety_margin": "Well-tolerated at 40-fold above efficacious dose"
    },
    "source": {
      "id": "kymr_corporate_2026",
      "slide": 56,
      "verified": false
    }
  },
  "investment_analysis": {
    "bull_case": [
      {
        "point": "Phase 1b efficacy matches Dupilumab",
        "evidence": "EASI -63% vs -52%; EASI-75 29% vs 28%; TARC -74% = -74%",
        "confidence": "High - multiple endpoints consistent",
        "source": {
          "id": "kymr_corporate_2026",
          "slide": 33,
          "verified": false
        }
      },
      {
        "point": "Oral convenience could transform market",
        "evidence": ">90% of biologic patients prefer oral; only 1% penetration today",
        "confidence": "High - survey data + low penetration",
        "source": {
          "id": "kymr_corporate_2026",
          "slide": 6,
          "verified": false
        }
      },
      {
        "point": "Clean safety with no conjunctivitis",
        "evidence": "0% vs 10-25% for Dupixent",
        "confidence": "Medium - need larger n to confirm",
        "source": {
          "id": "kymr_corporate_2026",
          "slide": 34,
          "verified": false
        }
      },
      {
        "point": "No plateau at Day 29 - efficacy may improve",
        "evidence": "EASI curve still declining; Dupixent improves through Week 16",
        "confidence": "Medium - need longer data",
        "source": {
          "id": "kymr_corporate_2026",
          "slide": 28,
          "verified": false
        }
      },
      {
        "point": "Biomarker data is objective validation",
        "evidence": "98% STAT6 degradation in blood, 94% in skin cannot be placebo effect",
        "confidence": "High - objective measurement",
        "source": {
          "id": "kymr_corporate_2026",
          "slide": 25,
          "verified": false
        }
      }
    ],
    "bear_case": [
      {
        "point": "Open-label design - placebo effect possible",
        "evidence": "AD has 25-35% placebo response; no control arm",
        "counter_argument": "Biomarker data (STAT6, TARC) is objective and matches Dupilumab",
        "probability": "30%"
      },
      {
        "point": "Only 29 days of treatment - durability unknown",
        "evidence": "Dupilumab trials were 16 weeks; long-term efficacy not proven",
        "counter_argument": "No plateau at Day 29 suggests continued improvement; some durability at Day 43 off treatment",
        "probability": "25%"
      },
      {
        "point": "Small sample size",
        "evidence": "n=22 is underpowered to detect safety signals or subgroup effects",
        "counter_argument": "Phase 2b will have ~200 patients",
        "probability": "20%"
      },
      {
        "point": "Competitive response from Dupixent",
        "evidence": "Sanofi/Regeneron have resources to defend $13B franchise",
        "counter_argument": "Hard to make Dupixent oral; degrader is novel mechanism",
        "probability": "Ongoing risk"
      }
    ],
    "key_debates": [
      {
        "question": "Can an oral degrader match an injectable biologic?",
        "bull_view": "Yes - 90%+ degradation = complete pathway blockade",
        "bear_view": "No - tissue distribution and half-life may differ",
        "what_resolves_it": "BROADEN2 EASI-75 at Week 16 vs placebo"
      },
      {
        "question": "Is the no-conjunctivitis signal real and differentiated?",
        "bull_view": "Yes - mechanistic (STAT6 downstream of IL-4R); 0% vs 10-25%",
        "bear_view": "No - too few patients; could emerge in larger trials",
        "what_resolves_it": "Phase 2b safety data with larger n"
      },
      {
        "question": "Will efficacy plateau or continue improving?",
        "bull_view": "Continue - no plateau at Day 29; Dupixent improves through Week 16",
        "bear_view": "Plateau - mechanism may have ceiling effect",
        "what_resolves_it": "BROADEN2 Week 16 time course data"
      }
    ],
    "probability_of_success": {
      "phase2b_to_phase3": "55%",
      "phase3_to_approval": "65%",
      "cumulative_pos": "36%",
      "methodology": "Historical Phase 2\u21923 success rates in dermatology + adjustment for strong biomarker data"
    }
  },
  "catalysts": [
    {
      "event": "BROADEN2 Phase 2b AD enrollment completion",
      "timing": "2026",
      "importance": "Medium",
      "what_to_watch": "Enrollment pace; any protocol amendments"
    },
    {
      "event": "BROADEN2 Phase 2b AD data",
      "timing": "Mid-2027",
      "importance": "Critical",
      "what_to_watch": [
        "EASI-75 at Week 16 (target \u226540%)",
        "Placebo delta (target \u226515%)",
        "vIGA-AD 0/1 response rate",
        "Safety - especially conjunctivitis incidence",
        "Dose response - which dose selected for Phase 3"
      ],
      "bull_scenario": {
        "outcome": "EASI-75 \u226545%, clean safety, clear dose selection",
        "stock_impact": "+50-100%",
        "rationale": "Confirms Dupixent-like efficacy in placebo-controlled setting; validates platform"
      },
      "bear_scenario": {
        "outcome": "EASI-75 <35% or safety signal emerges",
        "stock_impact": "-40-60%",
        "rationale": "Suggests Phase 1b was placebo effect; questions platform"
      },
      "consensus_expectation": "EASI-75 ~40%; modest beat may be priced in"
    },
    {
      "event": "BREADTH Phase 2b Asthma data",
      "timing": "Late 2027",
      "importance": "High",
      "what_to_watch": [
        "FEV1 improvement vs placebo",
        "FeNO reduction",
        "ACQ-5 response",
        "Any exacerbation signal"
      ],
      "why_it_matters": "Validates expansion beyond dermatology; asthma is 55M patient market"
    }
  ],
  "competitive_landscape": [
    {
      "competitor": "Dupixent (dupilumab)",
      "company": "Sanofi/Regeneron",
      "mechanism": "Anti-IL-4R\u03b1 antibody",
      "stage": "Approved",
      "sales": "$13B+ annually",
      "differentiation": {
        "administration": "Dupixent is SC injection Q2W; KT-621 is daily oral pill",
        "convenience": "Oral may expand access to patients who decline/can't tolerate injections",
        "safety": "Dupixent has 10-25% conjunctivitis; KT-621 has 0% so far",
        "initiation": "Dupixent requires loading dose, blood testing; KT-621 may be simpler"
      },
      "threat_level": "Incumbent - but hard to make oral"
    },
    {
      "competitor": "JAK inhibitors (Rinvoq, Cibinqo)",
      "company": "AbbVie, Pfizer",
      "mechanism": "JAK1 inhibitors",
      "stage": "Approved",
      "differentiation": {
        "safety": "JAKs have boxed warning (CV, malignancy, VTE); limits use",
        "selectivity": "KT-621 is more targeted (STAT6 only vs broad JAK pathway)"
      },
      "threat_level": "Medium - safety concerns limit JAK adoption"
    },
    {
      "competitor": "Other oral approaches",
      "examples": "Other degrader companies, IL-4/13 pathway small molecules",
      "status": "None in late-stage development for AD",
      "differentiation": "KT-621 is first oral STAT6 degrader in Phase 2"
    }
  ],
  "regulatory_path": {
    "fda_designations": [
      {
        "designation": "Fast Track",
        "indication": "Moderate-to-severe atopic dermatitis",
        "date": "December 11, 2025",
        "source": {
          "id": "kymr_corporate_2026",
          "slide": "TBD",
          "verified": false,
          "note": "Fast Track designation mentioned in company materials - slide reference needs verification"
        }
      }
    ],
    "potential_designations": "Breakthrough Therapy if Phase 2b positive",
    "expected_filing": "2029-2030 (if Phase 2b and Phase 3 successful)",
    "expected_approval": "2030-2031",
    "registration_strategy": "Parallel development in AD and asthma enables multiple NDA opportunities"
  },
  "sources": [
    {
      "title": "Kymera Therapeutics Corporate Presentation January 2026",
      "type": "Company Presentation",
      "date": "2026-01-15",
      "key_slides": {
        "13": "KT-621 summary",
        "14": "STAT6 biology",
        "15": "Market opportunity",
        "19": "BROADEN2 trial design",
        "20": "BREADTH trial design",
        "22": "Phase 1 HV data",
        "25": "Phase 1b STAT6 degradation",
        "26": "Biomarker summary",
        "28": "EASI results",
        "33": "Dupilumab comparison table",
        "34": "Safety summary"
      }
    },
    {
      "title": "Dupilumab SOLO Phase 3 trials",
      "type": "Published literature",
      "citation": "Simpson et al., NEJM 2016",
      "used_for": "Comparator benchmarks"
    }
  ]
}